Shanghai-based Zelixir Biotech, a leading provider of protein structure prediction and design services, has reportedly secured more than RMB 100 million (USD 14.1 million) in a Series A financing round. The funding was led by Qingdao Qingchi Venture Capital Fund, with additional investments from HM Capital, Hongfeng Investment, and Q Ventures. The proceeds from this round will be allocated to accelerate research and development and the construction of the company’s synthetic biology pipeline.
Zelixir Biotech’s Commitment to Synthetic Biology Innovation
Founded in 2021, Zelixir Bio is dedicated to revolutionizing the entire synthetic biology process through artificial intelligence (AI) and biological computing methodologies. The company’s approach encompasses reaction route design, mining, design, and transformation of related biological elements, automated high-throughput intelligent R&D, and production, all aimed at reducing costs and increasing efficiency.
The Development of ZCloud AI Computing Platform
Armed with competitive AI and synthetic biology capabilities, Zelixir Biotech is developing an AI computing platform branded “ZCloud”. This platform will leverage the company’s expertise in AI to enhance synthetic biology processes, further solidifying Zelixir Biotech’s position at the forefront of the industry.-Fineline Info & Tech
